Aspen drops Sigma bid by 8 percent

As analysts predicted, Aspen Pharmacare cut its buyout offer for Sigma Pharmaceuticals--to $552 million, an 8 percent drop--raising questions about whether a deal might actually happen. Report

Suggested Articles

While Lilly's 2018 launch Emgality is approved to prevent migraines, Reyvow is intended to treat them as they occur.

ICER's new draft review of RA drugs takes a different approach, reflecting how physicians treat the disease and the time horizon that's considered.

Johnson & Johnson is facing multibillion-dollar liabilities in thousands of talc and opioid cases. But that's not such a bad thing, one analyst said.